# Real-World Data Shows Lilly’s Tirzepatide Beats Novo’s Semaglutide at Weight Loss – Real-world evidence shows that Eli Lilly’s tirzepatide outperforms Novo Nordisk’s semaglutide in terms of weight loss. – Tirzepatide showed an average weight loss of 12.7% over 6 months, compared to 9.4% with semaglutide. – This data was presented at the American Diabetes Association’s Virtual 81st Scientific Sessions. – The results suggest that tirzepatide could be a promising option for patients struggling with obesity. A recent study has revealed that Eli Lilly’s tirzepatide may be more effective in promoting weight loss compared to Novo Nordisk’s semaglutide. In a real-world evidence study, tirzepatide demonstrated an impressive average weight loss of 12.7% over a period of 6 months, surpassing the 9.4% weight loss observed with semaglutide. These findings were presented at the American Diabetes Association’s Virtual 81st Scientific Sessions, shedding light on a potential new option for individuals battling obesity. The data suggests that tirzepatide could be a game-changer in the realm of weight loss medications, offering hope to those in need of effective solutions. ***Contact Mindful Evolution today to learn more about our weight loss programs and discover how we can support your journey towards a healthier lifestyle. Disclaimer: Individual results may vary. Our telehealth services are available in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.***